Found: 37
Select item for more details and to access through your institution.
Sensitivity and Specificity of the NETest: A Validation Study.
- Published in:
- Neuroendocrinology, 2021, v. 111, n. 6, p. 580, doi. 10.1159/000509866
- By:
- Publication type:
- Article
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms.
- Published in:
- Neuroendocrinology, 2020, v. 110, n. 5, p. 377, doi. 10.1159/000502383
- By:
- Publication type:
- Article
HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231186041
- By:
- Publication type:
- Article
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
- Published in:
- Current Oncology, 2022, v. 29, n. 2, p. 510, doi. 10.3390/curroncol29020046
- By:
- Publication type:
- Article
ACTH‐secreting pancreatic neuroendocrine neoplasms: A case‐series.
- Published in:
- Journal of Neuroendocrinology, 2023, v. 35, n. 10, p. 1, doi. 10.1111/jne.13336
- By:
- Publication type:
- Article
Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy.
- Published in:
- Journal of Neuroendocrinology, 2021, v. 33, n. 2, p. 1, doi. 10.1111/jne.12936
- By:
- Publication type:
- Article
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1187870
- By:
- Publication type:
- Article
Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors.
- Published in:
- Cancers, 2024, v. 16, n. 15, p. 2703, doi. 10.3390/cancers16152703
- By:
- Publication type:
- Article
Chemotherapy in Neuroendocrine Tumors.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4872, doi. 10.3390/cancers13194872
- By:
- Publication type:
- Article
An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Anatomic and Functional Imaging of Neuroendocrine Tumors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267167
- By:
- Publication type:
- Article
Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.265706
- By:
- Publication type:
- Article
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.267167
- By:
- Publication type:
- Article
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 362, doi. 10.2967/jnumed.123.267167
- By:
- Publication type:
- Article
Sequencing of Somatostatin-Receptor--Based Therapies in Neuroendocrine Tumor Patients.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 340, doi. 10.2967/jnumed.123.265706
- By:
- Publication type:
- Article
Sequencing of Somatostatin-Receptor--Based Therapies in Neuroendocrine Tumor Patients.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.265706
- By:
- Publication type:
- Article
Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1895, doi. 10.2967/jnumed.123.266185
- By:
- Publication type:
- Article
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.263041
- By:
- Publication type:
- Article
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.263041
- By:
- Publication type:
- Article
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.263041
- By:
- Publication type:
- Article
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Untitled.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Untitled.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%?
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. 294, doi. 10.1002/onco.13633
- By:
- Publication type:
- Article
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
- Published in:
- Oncologist, 2021, v. 26, n. 2, p. 115, doi. 10.1002/onco.13611
- By:
- Publication type:
- Article
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
- Published in:
- Oncologist, 2020, v. 25, n. 1, p. e48, doi. 10.1634/theoncologist.2019-0361
- By:
- Publication type:
- Article
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 8, p. 1293, doi. 10.1002/cncr.33364
- By:
- Publication type:
- Article